ASO-mediated PrP lowering for PRNP E200K: ION717 Phase 1/2a and the substrate-depletion rationale

Antisense oligonucleotide-mediated reduction of total PrP protein is the most clinically advanced therapeutic strategy for PRNP E200K genetic CJD. ION717 (Ionis Pharmaceuticals), administered intrathecally, targets PRNP mRNA to deplete PrP substrate and thereby block prion propagation. The Phase 1/2a PrProfile trial (NCT06153966) has enrolled 56 symptomatic patients across 16 global sites, with a third higher-dose cohort now being added after initial dose regimens showed suboptimal PrP lowering. The substrate-depletion approach is supported by strong genetic evidence: heterozygous PRNP loss-of-function is tolerated in humans, and PrP-knockout mice resist prion infection entirely.

Raymond et al. (2019, PMID: 31361599) demonstrated in prion-infected mice that prophylactic ASO-mediated PrP lowering extended survival by 61–98%, and a single injection near clinical onset extended survival by 55%. Minikel et al. (2020, PMID: 32776089) established that PrP lowering is disease-modifying across multiple prion strains and disease stages. The PrProfile trial completed enrollment in December 2024 with an encouraging safety profile reported as of March 2026. In parallel, a divalent siRNA program (Broad Institute/UMass) received IND clearance from FDA in March 2025 for symptomatic patients, providing a complementary RNA-targeting modality. Base editing (An et al., 2025, PMID: 39810005) achieved 50% PrP reduction and 52% lifespan extension in humanized prion mice via AAV-delivered cytosine base editor, but remains preclinical.

The first two ION717 dosing regimens did not achieve target PrP lowering levels, necessitating dose escalation. Intrathecal delivery requires repeated lumbar punctures every 2–3 months. FDA has placed a partial clinical hold preventing pre-symptomatic dosing, despite the fact that treatment before symptom onset — when irreversible neuronal loss has already begun — is likely to be most effective. E200K penetrance is incomplete (estimated 60–90% depending on population), complicating risk-benefit assessment for presymptomatic carriers. Mean survival from CJD symptom onset is approximately 7.6 months, leaving an extremely narrow treatment window for symptomatic patients. CSF biomarkers (RT-QuIC, PrP levels, NfL) for presymptomatic monitoring are improving but not yet validated for triggering preventive intervention.